secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001842952-22-000108
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context reports preliminary Phase 2 data for ONA-XR: 4-month PFS rate of 44% in metastatic breast cancer
--------------------------------------------------------------------------------

- 4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.
- ONA-XR combined with fulvestrant showed favorable safety and tolerability in second- or third-line setting.
- Previously disclosed endometrial cancer data showed 4-month PFS rate of 77% with anastrozole combination.
- ELONA Phase 1b/2 trial combining ONA-XR with elacestrant; Phase 1b data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000108/0001842952-22-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000108/cntx-20221207.htm
  HTML page:      https://secwatch.observer/filing/0001842952-22-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer